Holen Sie sich die Stockscreener-App
8.19
1.81%
-0.11
Handel nachbörslich:
8.16
-0.03
-0.37%
Schlusskurs vom Vortag:
$8.30
Offen:
$8.23
24-Stunden-Volumen:
142.99K
Relative Volume:
0.47
Marktkapitalisierung:
$174.52M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-52.07M
KGV:
-39.43
EPS:
-0.2077
Netto-Cashflow:
$-44.93M
1W Leistung:
-10.34%
1M Leistung:
-16.58%
6M Leistung:
-18.85%
1J Leistung:
-38.33%
1-Tages-Spanne:
$8.09
$8.43
1-Wochen-Bereich:
$7.8001
$9.16
52-Wochen-Spanne:
$6.50
$19.85
Cybin Inc Stock (CYBN) Company Profile
Firmenname
Cybin Inc
Sektor
Branche
Telefon
908 764 8385
Adresse
100 King Street West, Suite 5600, Toronto
Vergleichen Sie CYBN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CYBN
Cybin Inc
|
8.19 | 174.52M | 0 | -52.07M | -44.93M | -0.2077 |
|
VRTX
Vertex Pharmaceuticals Inc
|
479.79 | 121.85B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
698.74 | 76.83B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.67 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.75 | 30.69B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
271.80 | 29.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Cybin Inc Stock (CYBN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-11-19 | Herabstufung | Maxim Group | Buy → Hold |
Cybin Inc Aktie (CYBN) Neueste Nachrichten
Wall Street Analysts Think Cybin Inc. (CYBN) Could Surge 988.67%: Read This Before Placing a Bet - MSN
How to Take Advantage of moves in (CYBN) - Stock Traders Daily
Cybin (OTCMKTS:CLXPF) Stock Price Down 2.5%Should You Sell? - MarketBeat
Revolutionizing Mental Health Through Psychedelic Therapeutics | by Dr. Gleb Tsipursky | Feb, 2025 - DataDrivenInvestor
Cybin (NYSE:CYBN) Price Target Cut to $150.00 by Analysts at HC Wainwright - MarketBeat
Cybin (OTCMKTS:CYBN) Trading Up 1.2%Here's Why - MarketBeat
Canaccord cuts Cybin stock target to $73, maintains Buy rating - MSN
Cybin (NYSE:CYBN) Price Target Lowered to $73.00 at Canaccord Genuity Group - MarketBeat
Cybin stock price target cut to $150 at H.C. Wainwright - MSN
Cybin stock price target cut to $150 at H.C. Wainwright By Investing.com - Investing.com Australia
Canaccord cuts Cybin stock target to $73, maintains Buy rating By Investing.com - Investing.com Nigeria
(CYBN) Investment Analysis - Stock Traders Daily
Cybin sees third-quarter loss on R&D costs, advances clinical programs - Green Market Report
Cybin Accelerates PARADIGM Program for Depression Treatment - TipRanks
Cybin's Depression Drug Shows Perfect Response Rate, Advances to Pivotal Phase 3 with C$136M War Chest - StockTitan
Upstart (UPST) Reports Earnings Tomorrow: What To Expect - The Globe and Mail
Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights - Business Wire
Trade thoughts for Gold futures - The Globe and Mail
Is Rigetti Computing a Millionaire-Maker Stock? - The Globe and Mail
HC Wainwright Forecasts Cybin's Q3 Earnings (NYSE:CYBN) - MarketBeat
What is HC Wainwright's Estimate for Cybin FY2029 Earnings? - MarketBeat
Cybin (OTCMKTS:CLXPF) Shares Up 1.9%What's Next? - MarketBeat
What is HC Wainwright's Forecast for Cybin FY2029 Earnings? - MarketBeat
How To Trade (CYBN) - Stock Traders Daily
HC Wainwright Issues Optimistic Estimate for Cybin Earnings - Defense World
Wall Street Analysts Believe Cybin Inc. (CYBN) Could Rally 952.23%: Here's is How to Trade - Yahoo Finance
HC Wainwright Has Bearish Outlook for Cybin FY2029 Earnings - Defense World
H.C. Wainwright maintains $190 target on Cybin Inc. shares - MSN
H.C. Wainwright maintains $190 target on Cybin Inc. shares By Investing.com - Investing.com South Africa
HC Wainwright Reiterates "Buy" Rating for Cybin (NYSE:CYBN) - MarketBeat
Cybin (OTCMKTS:CYBN) Shares Up 1.8%Should You Buy? - MarketBeat
5-HT2 Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire Inc.
(CYBN) Trading Signals - Stock Traders Daily
Finanzdaten der Cybin Inc-Aktie (CYBN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.95%
0.31%
Kapitalisierung:
|
Volumen (24h):